TRVN - Trevena Inc. Market Capitalization-to-Revenue Ratio
Stringent FDA requirements and patent protection for molecules create significant barriers to entry for competitors. The current price-to-sales ratio reflects valuation volatility, with the value fixed at 4.80. While the inclusion of analgesics in hospital formularies ensures stable sales, weak cash flows from Olinvyk and the need for operational restructuring are constraining the financial growth of Trevena, Inc. (TRVN).
Trevena, Inc (TRVN) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
TRVN - Company Net Income|Net Profit Forecast Trevena, Inc.|TRVN - Price to Earnings Ratio|Price to Future Earnings Ratio Trevena Inc.|TRVN - PEG Multiple|Company Value to EBITDA Trevena, Inc|TRVN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Trevena|TRVN - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months trevena.com|TRVN - Earnings per share growth in current year|Expected net earnings per share growth next year Trevena, Inc.
- total revenue and sales volume data:
Summary company analytics:trevena.com
Stable sales of Trevena, Inc. (TRVN) analgesics via hospital formularies make revenue a reliable basis for business valuation. By analyzing the company's revenue multiples, an investor determines how much the market is willing to pay per unit of sales, which helps identify whether the asset is overbought or faces a risk of stagnation when comparing the current ratio to its historical extremes.
Competitors of Trevena, Inc.
P/S Multiple biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Coefficient ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Market Cap to Revenue Catalyst Pharma (CPRX)|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Price-to-Revenue Coefficient Harmony Corp|Biohaven Ltd. - Market Cap to Revenue|Market Cap to Sales Volume AMLX (amylyx.com)|TRVI - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PRAX (Praxis Precision Medicines Inc)|AVXL (Anavex Corp) - Market Cap to Revenue|CBLL (CeriBell EEG) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Prothena Biosciences|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|Price-to-Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Revenue Ratio|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR: Market Cap to Revenue|NMRA - P/S Multiple|Scilex (SCLX) - Price-to-Revenue Ratio|Tevogen Bio Holdings Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alpha Cognition Inc|Price to Sales Cognition Therapeutics Inc. CGTX|Market Cap to Revenue IKT (Inhibikase Therapeutics)|Market Cap to Sales Volume SAVA|Price-to-Revenue Ratio Assertio ASRT|Market Capitalization-to-Revenue Ratio COYA|VistaGen Therapeutics Inc - P/S Multiple|Price to Sales Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|CRVO (cervomed.com) - Price-to-Revenue Ratio|ATHE (Alterity Therapeutics Ltd.) - P/S Multiple|Price to Sales Clene Nanomedicine CLNN|Price-to-Revenue Ratio PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Market Cap to Revenue Ratio|P/S Multiple RLMD (Relmada Therapeutics)|P/S Multiple annovisbio.com ANVS|GRCE: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AIFF (Firefly Neuroscience, Inc.)|KLTO: P/S Multiple|NRSN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Reviva Pharmaceuticals|Market Cap to Revenue Ratio MTVA (MetaVia, Inc.)|P/S Multiple NRXS|Market Cap to Revenue heliusmedical.com HSDT|Passage Bio - Market Cap to Revenue|Price-to-Revenue Coefficient Neuphoria Therapeutics, Inc. (NEUP)|NERV: Market Cap to Revenue|athira.com - Market Cap to Sales Volume|Addex Therapeutics Ltd (ADXN) - Price-to-Revenue Ratio|Alzamend Neuro - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CYCN|Price-to-Revenue Ratio PTIX|Price-to-Revenue Ratio Pasithea Therapeutics (KTTA)|cortigent.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Avenue Therapeutics, Inc. ATXI|BCLI: Market Cap to Revenue Ratio|Cara Therapeutics, Inc - P/S Multiple|Price to Sales Chromocell|ELYM (eliemtx.com) - Market Cap to Revenue|Intra-Cellular Therapies, Inc. (ITCI) - P/S Multiple|Price-to-Revenue Ratio Longboard Pharmaceuticals, Inc.|MRNS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NKGen (NKGN)|NRBO - Price to Sales|Sage Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume SNPX (synaptogen.com)|VIGL - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio WENA (anewmeds.com)|CERE: P/S Multiple
